The stock price of Novartis AG ADR (NYSE: NVS) has surged by 1.02 when compared to previous closing price of 112.28, but the company has seen a 8.03% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-20 that I’ve added Novo Nordisk and Novartis to boost The Dividend Income Accelerator’s healthcare allocation and global diversification, reducing overall risk and volatility. Both companies are attractively valued, trading below sector averages, and offer strong growth metrics and robust dividend yields. Novo Nordisk and Novartis each provide a compelling blend of dividend income and growth potential, aligning perfectly with our investment strategy.
Is It Worth Investing in Novartis AG ADR (NYSE: NVS) Right Now?
The price-to-earnings ratio for Novartis AG ADR (NYSE: NVS) is above average at 17.75x. The 36-month beta value for NVS is also noteworthy at 0.57. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 9 rating it as “hold,” and 2 rating it as “sell.”
The public float for NVS is 1.90B, and at present, short sellers hold a 0.24% of that float. The average trading volume of NVS on May 21, 2025 was 2.39M shares.
NVS’s Market Performance
The stock of Novartis AG ADR (NVS) has seen a 8.03% increase in the past week, with a 1.80% rise in the past month, and a 5.69% gain in the past quarter. The volatility ratio for the week is 1.66%, and the volatility levels for the past 30 days are at 1.49% for NVS. The simple moving average for the past 20 days is 2.28% for NVS’s stock, with a 4.08% simple moving average for the past 200 days.
NVS Trading at 3.05% from the 50-Day Moving Average
After a stumble in the market that brought NVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.20% of loss for the given period.
Volatility was left at 1.49%, however, over the last 30 days, the volatility rate increased by 1.66%, as shares surge +2.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.69% upper at present.
During the last 5 trading sessions, NVS rose by +7.85%, which changed the moving average for the period of 200-days by +0.32% in comparison to the 20-day moving average, which settled at $110.89. In addition, Novartis AG ADR saw 16.56% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVS starting from Kowalski Robert William, who proposed sale 1,212 shares at the price of $113.28 back on Apr 30 ’25. After this action, Kowalski Robert William now owns shares of Novartis AG ADR, valued at $137,297 using the latest closing price.
Kowalski Robert William, the Officer of Novartis AG ADR, proposed sale 6,566 shares at $111.72 during a trade that took place back on Aug 12 ’24, which means that Kowalski Robert William is holding shares at $733,572 based on the most recent closing price.
Stock Fundamentals for NVS
Current profitability levels for the company are sitting at:
- 0.3 for the present operating margin
- 0.76 for the gross margin
The net margin for Novartis AG ADR stands at 0.24. The total capital return value is set at 0.23. Equity return is now at value 32.95, with 13.24 for asset returns.
Based on Novartis AG ADR (NVS), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at 0.61. The debt to equity ratio resting at 0.81. The interest coverage ratio of the stock is 20.17.
Currently, EBITDA for the company is 20.71 billion with net debt to EBITDA at 1.11. When we switch over and look at the enterprise to sales, we see a ratio of 4.5. The receivables turnover for the company is 6.1for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.79.
Conclusion
In summary, Novartis AG ADR (NVS) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
